Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25926072 | 0.87 | KCNH2 (0.35) | MYCGAATSHRKDM4EMEN1 | |
| SCHEMBL25929342 | 0.81 | POLB (0.32) | MYCGAAMEN1POLBMAPT | |
| SCHEMBL25925973 | 0.78 | — | — | |
| SCHEMBL25929460 | 0.75 | RPS6KA3 (0.33) | — | |
| SCHEMBL25926039 | 0.68 | PLG (0.30) | — | |
| SCHEMBL25926052 | 0.67 | KCNH2 (0.32) | KDM4EMEN1MAPTKMT2AKCNH2 | |
| SCHEMBL25925878 | 0.66 | BRD4 (0.32) | MEN1MAPTKMT2A | |
| SCHEMBL25926046 | 0.66 | KCNH2 (0.31) | KDM4EMEN1MAPTKMT2AKCNH2 | |
| SCHEMBL25930230 | 0.65 | MEN1 (0.31) | KDM4EMEN1MAPTKMT2AKCNH2 | |
| SCHEMBL19725301 | 0.63 | MEN1 (0.36) | GAAKDM4EMEN1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242523-A1 | COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE | FUJIFILM CORPORATION (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20230242523-A1 | COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE | FUJIFILM CORPORATION (JP) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242523-A1 | COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE | AR, MAPT, NR5A1 | MYC 616/4885GAA 4080/4885TSHR 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.